A Phase 4 interventional study of Median nerve electrical stimulation treatment and Huperzine A injection in Cognitive Impairment After Brain Injury, sponsored by Wanbangde Pharmaceutical Group Co., LTD. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Wanbangde Pharmaceutical Group Co., LTD · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Brain Injuries with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Brain Injuries · China.
Among the 47 studies in Brain Injuries with a site in China, this one is the 16th largest by planned enrollment of the 23 interventional ones that give a count, is one of 11 that started in 2024, is one of 5 in phase 4, reaches primary completion later than 10 of the 17 other live ones, and was the 29th registered.
947 studies on the registry are indexed under Brain Injuries; 236 are open to participants now.
Browse Brain Injuries studies →17 of the 47 studies in Brain Injuries with a site in China are open now. Recruiting first, the newest first:
Guizhou Medical University · Sites in China
Ages 18–75
Xijing Hospital · Sites in China
Ages 18–65
RenJi Hospital · Sites in China
Ages 18+
Beijing Sanbo Brain Hospital · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 153 Brain Injuries studies recruiting now, 76 (50%) set no upper age limit and 55 (36%) stop at 75 or younger; 39 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 41 across 613 interventional studies indexed under Brain Injuries.
Median enrollment 96 across the 23 interventional studies, 50 across the 24 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 47 have an industry lead sponsor. The 10 most frequent:
Wanbangde Pharmaceutical Group Co., LTD is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Wanbangde Pharmaceutical Group Co., LTD has 1 study filed under Brain Injuries — fewer than ten, so there is no comparison to draw.
4 of the studies in Brain Injuries with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06930586The First Affiliated Hospital of Zhengzhou UniversityPrognostic Value of Neurometabolic Networks in CRC (PVNM-CRC) | 2026-12-31 |
| NCT06704334Wanbangde Pharmaceutical Group Co., LTDThe Study of Ginkgo Leaf Dropping Pills and Huperzine A Injection Combined With Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury | 2026-12-31 |
| NCT07716787Shengli Oilfield HospitalBrain Monitoring During PEEP-Based Respiratory Therapy in Critically Ill Patients | 2027-02-01 |
| NCT07481656Anhui Provincial HospitalEffects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 47 studies in Brain Injuries with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will conduct a single-center clinical trial to explore the initial therapeutic effect of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment.
Specific experimental research methods were randomized, controlled, single-center, exploratory clinical study, through the treatment of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment, to observe the effects of their neuroprotection and cognitive function improvement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The optimal median nerve electrical stimulation treatment was given
Other: Median nerve electrical stimulation treatment
Huperzine A injection can be administered before median nerve electrical stimulation to improve the therapeutic effect of electrical stimulation. Huperzine A injection: intramuscular injection, 1ml,0.2mg once a day, the course of treatment was 7 days.
Other: Median nerve electrical stimulation treatment · Drug: Huperzine A injection
Huperzine A injection can be administered before median nerve electrical stimulation to improve the therapeutic effect of electrical stimulation. After the end of the electrical stimulation treatment, ginkgo biloba dropping pills were given as long-term administration to maintain the therapeutic effect. Huperzine A injection: intramuscular injection, 1ml,0.2mg once a day, the course of treatment was 7 days. Ginkgo leaf dropping pills: Oral, each pill weighs 63mg, 5 pills/time, 3 times/day, the course of treatment is 3 months.
Other: Median nerve electrical stimulation treatment · Drug: Huperzine A injection · Drug: Ginkgo leaf dropping pill
Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of neurons and promote the signal transmission between neurons. Its mechanism of action includes the regulation of neurotransmitter acetylcholine, thereby enhancing cognitive function.
intramuscular
oral
to assess the Mini-Mental State Examination (MMSE) score
Mini-Mental State Examination (MMSE): total score ranges from 0 to 30. Higher scores indicate better cognitive function.
Time frame: baseline,Day10,Day90
to assess the Montreal Cognitive Assessment (MoCA) score
Montreal Cognitive Assessment (MoCA): total score ranges from 0 to 30. Higher scores indicate better cognitive function.
Time frame: baseline,Day10,Day90
to assess the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) score
Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog): total score ranges from 0 to 70. Higher scores indicate worse cognitive performance.
Time frame: baseline,Day10,Day90
to assess the Hamilton Depression Rating Scale (HAMD) score
Hamilton Depression Rating Scale (HAMD-24 item): total score ranges from 0 to 76. Higher scores indicate more severe depressive symptoms.
Time frame: baseline,Day10,Day90
to assess the Hamilton Anxiety Rating Scale (HAMA) score
Hamilton Anxiety Rating Scale (HAMA): total score ranges from 0 to 56. Higher scores indicate more severe anxiety symptoms.
Time frame: baseline,Day10,Day90
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Huperzine A
Wanbangde Pharmaceutical Group Co., LTD